GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rapid Therapeutic Science Laboratories Inc (OTCPK:RTSL) » Definitions » 10-Year RORE %

Rapid Therapeutic Science Laboratories (Rapid Therapeutic Science Laboratories) 10-Year RORE % : -0.88% (As of Jun. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Rapid Therapeutic Science Laboratories 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Rapid Therapeutic Science Laboratories's 10-Year RORE % for the quarter that ended in Jun. 2023 was -0.88%.

The industry rank for Rapid Therapeutic Science Laboratories's 10-Year RORE % or its related term are showing as below:

RTSL's 10-Year RORE % is ranked worse than
57.68% of 397 companies
in the Medical Devices & Instruments industry
Industry Median: 2.45 vs RTSL: -0.88

Rapid Therapeutic Science Laboratories 10-Year RORE % Historical Data

The historical data trend for Rapid Therapeutic Science Laboratories's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapid Therapeutic Science Laboratories 10-Year RORE % Chart

Rapid Therapeutic Science Laboratories Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Dec21 Dec22
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Rapid Therapeutic Science Laboratories Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -0.65 -0.88

Competitive Comparison of Rapid Therapeutic Science Laboratories's 10-Year RORE %

For the Medical Devices subindustry, Rapid Therapeutic Science Laboratories's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rapid Therapeutic Science Laboratories's 10-Year RORE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Rapid Therapeutic Science Laboratories's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Rapid Therapeutic Science Laboratories's 10-Year RORE % falls into.



Rapid Therapeutic Science Laboratories 10-Year RORE % Calculation

Rapid Therapeutic Science Laboratories's 10-Year RORE % for the quarter that ended in Jun. 2023 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( 0.01--0.322 )/( -37.747-0 )
=0.332/-37.747
=-0.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2023 and 10-year before.


Rapid Therapeutic Science Laboratories  (OTCPK:RTSL) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Rapid Therapeutic Science Laboratories 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of Rapid Therapeutic Science Laboratories's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rapid Therapeutic Science Laboratories (Rapid Therapeutic Science Laboratories) Business Description

Traded in Other Exchanges
N/A
Address
5580 Peterson Lane, Suite 120, Dallas, TX, USA, 75201
Rapid Therapeutic Science Laboratories Inc is a biotech company specializing in natural-based relief through aerosol delivery of cannabinoids to the systemic bloodstream through the pulmonary route of administration. The company manufactures its own branded metered dose inhalers (MDI) under the nhaler name using proprietary blends of pure cannabinoids such as cannabidiol (CBD) and cannabigerol (CBG). In addition, the company manufactures other aerosol devices for the delivery of cannabinoids other than MDI such as sublingual sprays.
Executives
Henry Anthony Punzi director 1932 WALNUT PLAZA, CARROLLTON TX 75006
Scott Suggs Justin director 639 SWORD BRIDGE DR., LEWISVILLE TX 75056
Sean Paul Berrier 10 percent owner 7108 DUFFIELD DR., DALLAS TX 75248
Schmidt Donal Ray Jr. director, 10 percent owner, officer: President and CEO 5580 PETERSON LANE, SUITE 200, DALLAS TX 75240
Ryan Casey Johnson director, officer: Chief Operating Officer 2307 CASTLE ROCK RD, CARROLTON TX 75007
Texas Mdi, Inc. 10 percent owner 5580 PETERSON LANE, SUITE 200, DALLAS TX 75240
D Hughes Watler director, officer: CFO 2323 S. VOSS ROAD, STE. 510-12, HOUSTON TX 77057
Steve Bond director, officer: CFO 28839 PUJOL ST., #832, TEMECULA CA 92590
Brent Willson director, officer: CEO and President 5271 CAMINITO EXQUISITO, SAN DIEGO CA 92130